表紙：mTOR阻害剤の世界市場：薬剤タイプ、適応症、投与経路、流通チャネル、地域別 - 規模、シェア、展望、機会分析（2022年～2030年）

市場調査レポート

商品コード

1086012

mTOR阻害剤の世界市場：薬剤タイプ、適応症、投与経路、流通チャネル、地域別 - 規模、シェア、展望、機会分析（2022年～2030年）

mTOR Inhibitors Market, by Drug Type, By Indication, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日: 2022年05月16日 | 発行: Coherent Market Insights

| ページ情報: 英文 175 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 704,610円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,096,060円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,565,800円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.58円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のmTOR阻害剤市場は、規制機関からの製品承認の増加による予測期間中の成長促進が予想されています。

当レポートでは、世界のmTOR阻害剤市場について調査し、市場力学、COVID-19の影響、セグメント・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

イントロダクション
北米
米国
カナダ
ラテンアメリカ
ブラジル
メキシコ
アルゼンチン
その他ラテンアメリカ
欧州
ドイツ
英国
フランス
イタリア
スペイン
ロシア
その他欧州
アジア太平洋
中国
インド
日本
オーストラリア
韓国
ASEAN
その他アジア太平洋
中東
GCC
イスラエル
その他中東
アフリカ
南アフリカ
中央アフリカ
北アフリカ

第10章競合情勢

企業プロファイル
- Novartis AG
- Hikma Pharmaceuticals PLC.
- Par Pharmaceutical
- Teva Pharmaceutical Industries Ltd.
- Reddy's Laboratories Ltd.
- Zydus Cadilla
- Pfizer, Inc.
- Biocon
- Alkem Laboratories Ltd.
- Accord Healthcare Inc.
- Gland Pharma Ltd.
- Apotex Inc.
- Glenmark Pharmaceuticals Ltd.
アナリストの見解

第11章セクション

Product Code: CMI5019

Mammalian target of rapamycin (mTOR) is a protein kinase, which regulates growth factors that stimulate cell growth and angiogenesis. Mammalian target of rapamycin (mTOR) inibitors controls the cell division, and controls the growth of cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow. Mammalian target of rapamycin (mTOR) inhibitors are used in the treatment of renal cancer and it is being studied for use in other types of cancers. mTOR are indicated for the treatment of breast cancer, lymphangioleiomyomatosis, neuroendocrine carcinoma, organ transplant, pancreatic cancer, renal cell carcinoma, tuberous sclerosis complex and others. Mammalian target of rapamycin (mTOR), drugs are- Everolimus, Temsirolimus, and Sirolimus. Mammalian target of rapamycin (mTOR) has common and serious class side effects of mTOR inhibitors include non-infectious pneumonitis, metabolic disorders and mucosal toxicity.

Market Dynamics

Increasing product approvals from regulatory bodies is expected to drive the growth of global mTOR Inhibitors market during the forecast period. For instance, in June 2021, Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical announced that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Everolimus Tablets (generic for Zortress). Everolimus tablets will be in strength of 0.25mg, 0.5mg, and 0.75mg.

Increasing number of prevalence of renal cell carcinoma is expected to drive the growth of global mTOR inhibitors market. For instance, according to an article published by the U.S. Department of Health and Human Services, published in 2018, there were an estimated 582,727 people living with kidney and renal pelvis cancer in the U.S.

Key features of the study:

This report provides an in-depth analysis of global mTOR inhibitors market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global mTOR inhibitors market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.

Key companies covered as a part of this study include Novartis AG, Hikma Pharmaceuticals PLC., Par Pharmaceutical, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Zydus Cadilla, Pfizer, Inc., Biocon, Alkem Laboratories Ltd., Accord Healthcare Inc., Gland Pharma Ltd., Apotex Inc., and Glenmark Pharmaceuticals Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global mTOR inhibitors market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.

Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global mTOR inhibitors

Detailed Segmentation:

Global mTOR Inhibitors Market, By Drug Type:
- Everolimus
- Temsirolimus
- Sirolimus
Global mTOR Inhibitors Market, By Indication:
- Oncology
- Immunosuppressant
- Organ Transplantation
- Others
Global mTOR Inhibitors Market, By Route of Administration:
- Oral
- Intravenous
Global mTOR Inhibitors Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global mTOR Inhibitors Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Novartis AG*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Hikma Pharmaceuticals PLC.
- Par Pharmaceutical
- Teva Pharmaceutical Industries Ltd.
- Reddy's Laboratories Ltd.
- Zydus Cadilla
- Pfizer, Inc.
- Biocon
- Alkem Laboratories Ltd.
- Accord Healthcare Inc.
- Gland Pharma Ltd.
- Apotex Inc.
- Glenmark Pharmaceuticals Ltd.

"" marked represents similar segmentation in other categories in the respective section.*

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Development
PEST Analysis
Regulatory Scenario
Pipeline Analysis
New Product Launch/ Approval
Epidemiology
Market Trends

4. Global mTOR Inhibitors Market - Impact of Coronavirus (Covid-19) Pandemic

Economic Impact
COVID-19 Epidemiology
Government Initiatives to Combat COVID-19

5. Global mTOR Inhibitors Market, By Drug Type, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Everolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Temsirolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Sirolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

6. Global mTOR Inhibitors Market, By Indication, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Immunosuppressant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Organ Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

7. Global mTOR Inhibitors Market, By Route of Administration, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

8. Global mTOR Inhibitors Market, By Distribution Channel, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

9. Global mTOR Inhibitors Market, By Region, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2030
- Regional Trends
North America
- Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2030 (US$ Mn)
South Africa
Central Africa
North Africa

10. Competitive Landscape

Company Profiles
- Novartis AG
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Hikma Pharmaceuticals PLC.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Par Pharmaceutical
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Teva Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Reddy's Laboratories Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Zydus Cadilla
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Pfizer, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Biocon
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Alkem Laboratories Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Accord Healthcare Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Gland Pharma Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Apotex Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Glenmark Pharmaceuticals Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
Analyst Views

11. Section

References
Research Methodology
About Us and Sales Contact

mTOR阻害剤の世界市場：薬剤タイプ、適応症、投与経路、流通チャネル、地域別 - 規模、シェア、展望、機会分析（2022年～2030年）

mTOR Inhibitors Market, by Drug Type, By Indication, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

目次

第1章調査目的・前提条件

第2章市場概要

第3章市場力学、規制、および動向分析

第4章世界のmTOR阻害剤市場-コロナウイルス（COVID-19）パンデミックの影響

第5章世界のmTOR阻害剤市場：薬剤タイプ別

第6章世界のmTOR阻害剤市場：適応症別

第7章世界のmTOR阻害剤市場：投与経路別

第8章世界のmTOR阻害剤市場：流通チャネル別

第9章世界のmTOR阻害剤市場：地域別

第10章競合情勢

第11章セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

"" marked represents similar segmentation in other categories in the respective section.*

Table of Contents

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global mTOR Inhibitors Market - Impact of Coronavirus (Covid-19) Pandemic

5. Global mTOR Inhibitors Market, By Drug Type, 2017 - 2030 (US$ Million)

6. Global mTOR Inhibitors Market, By Indication, 2017 - 2030 (US$ Million)

7. Global mTOR Inhibitors Market, By Route of Administration, 2017 - 2030 (US$ Million)

8. Global mTOR Inhibitors Market, By Distribution Channel, 2017 - 2030 (US$ Million)

9. Global mTOR Inhibitors Market, By Region, 2017 - 2028 (US$ Million)

10. Competitive Landscape

11. Section

mTOR阻害剤の世界市場：薬剤タイプ、適応症、投与経路、流通チャネル、地域別 - 規模、シェア、展望、機会分析（2022年～2030年）

mTOR Inhibitors Market, by Drug Type, By Indication, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学、規制、および動向分析

第4章 世界のmTOR阻害剤市場-コロナウイルス（COVID-19）パンデミックの影響

第5章 世界のmTOR阻害剤市場：薬剤タイプ別

第6章 世界のmTOR阻害剤市場：適応症別

第7章 世界のmTOR阻害剤市場：投与経路別

第8章 世界のmTOR阻害剤市場：流通チャネル別

第9章 世界のmTOR阻害剤市場：地域別

第10章 競合情勢

第11章 セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global mTOR Inhibitors Market - Impact of Coronavirus (Covid-19) Pandemic

5. Global mTOR Inhibitors Market, By Drug Type, 2017 - 2030 (US$ Million)

6. Global mTOR Inhibitors Market, By Indication, 2017 - 2030 (US$ Million)

7. Global mTOR Inhibitors Market, By Route of Administration, 2017 - 2030 (US$ Million)

8. Global mTOR Inhibitors Market, By Distribution Channel, 2017 - 2030 (US$ Million)

9. Global mTOR Inhibitors Market, By Region, 2017 - 2028 (US$ Million)

10. Competitive Landscape

11. Section

第1章調査目的・前提条件

第2章市場概要

第3章市場力学、規制、および動向分析

第4章世界のmTOR阻害剤市場-コロナウイルス（COVID-19）パンデミックの影響

第5章世界のmTOR阻害剤市場：薬剤タイプ別

第6章世界のmTOR阻害剤市場：適応症別

第7章世界のmTOR阻害剤市場：投与経路別

第8章世界のmTOR阻害剤市場：流通チャネル別

第9章世界のmTOR阻害剤市場：地域別

第10章競合情勢

第11章セクション

"" marked represents similar segmentation in other categories in the respective section.*